Can Outlook Break The Cycle With Fresh FDA Meeting On Ophthalmic Bevacizumab?

Firm Says Latest CRL ‘Unexpected’ And ‘Inconsistent’ With Evidence

 
• By Dave Wallace
  
Can Outlook stop the cycle of FDA rejection? (Shutterstock)

More from Biosimilars

More from Products